Treating Solid Tumors With Personalized Immunotherapy: Julian Molina, MD, PhD

The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.

“We envision Tmod being a game changer for immunotherapy because it allows you to do personalized treatment... it's tailoring the treatment of a patient’s cancer using immunotherapy to their particular tumor type.”

A2 Biotherapeutics presented data on the observational BASECAMP-1 study (NCT04981119) and preclinical data on mesothelin (MSLN) and carcinoembryonic antigen (CEA)-targeted Tmod chimeric antigen receptor (CAR) T-cell therapies at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 10-14, 2021.1

Tmod cell therapies were efficacious in preclinical studies. The BASECAMP-1 study is identifying patients with relapsed solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH) as future recipients of Tmod cell therapy.2 HLA LOH is present in approximately 13% of all solid tumors and up to 33% of pancreatic cancers. The study is also assessing leukapheresis and manufacturing feasibility for future Tmod therapies. 

GeneTherapyLive spoke with Molina to learn more about developing personalized immunotherapies for solid tumors and the value of HLA LOH in targeting these tumors.

1. A2 Bio to Highlight Program Updates in Two Presentations at SITC 2021. News release. A2 Bio Therapeutics. November 1, 2021.
2. Molina J, Go W, Kopetz S, et al. BASECAMP-1: an observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy. Presented at: 2021 SITC Annual Meeting; November 10-14, 2021; Washington, DC. Abstract 491.
Related Videos
Natalie Goedeker, CPNP, on Supporting Gene Therapy’s Ascendance in Muscular Dystrophies
Angela Genge, MD, FRCPC, eMBA, on Targeting STMN2 to Rescue Neurons in ALS
© 2023 MJH Life Sciences

All rights reserved.